explore -WSS

explore

author：explore 2025-08-25 08:46:42 - browse：8

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： PrEP can help anyone prevent HIV. Why do so few people take it?

WSS

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Severe heat forecast: Where scorching temperatures will persist over the next week

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Fertility clinic egg and embryo storage is a disaster

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Abbott's new stent may help patients with peripheral artery disease

leisure time

explore

knowledge

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What a koala virus tells us about the human genome

State Dept. review finds Biden bears some blame for Afghanistan failures

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Drug repurposing or repositioning? The language matters

Statins reduce cardiovascular risk in people living with HIV

Jerome Adams on the need for new antivirals for Covid

FDA approves first blood sugar monitor without finger pricks

Medical leaders decry Supreme Court decision on affirmative action

HHS suspends federal funding for EcoHealth Alliance

explore

What a koala virus tells us about the human genome

What a koala virus tells us about the human genome

Galapagos to make CAR

How a key Senate committee is planning to regulate PBMs

Where does female orgasm come from? Scientists think they know

Inside the culture of fear in the White House science office of Eric Lander

leisure time

Wikipedia

focus

leisure time